Stapled peptide-based membrane fusion inhibitors of hepatitis C virus

被引：60
|
作者：
Cui, Hong-Kui [1 ]
Qing, Jie [1 ]
Guo, Ye [1 ]
Wang, Yu-Jia [1 ]
Cui, Li-Jia [2 ,3 ]
He, Tian-Hua [2 ,3 ]
Zhang, Linqi [2 ,3 ]
Liu, Lei [1 ]
机构：
[1] Tsinghua Univ, Dept Chem, Tsinghua Peking Ctr Life Sci,Minist Educ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China
[3] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing 100084, Peoples R China
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2013年 / 21卷 / 12期
基金：
中国国家自然科学基金;
关键词：
Hepatitis C virus; Stapled peptide; Protein-protein interaction; CELL-CULTURE SYSTEMS; B TYPE-I; OLEFIN METATHESIS; ALPHA-HELICES; BH3; HELIX; CD81; ENTRY; INFECTION; PROTEINS; RECEPTOR;
D O I：
10.1016/j.bmc.2013.02.011
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The strategy of peptide stapling was used to develop new molecules to inhibit the hepatitis C virus infection via disrupting the binding of HCV envelope glycoprotein E2 with human cell surface protein CD81. The peptide sequence was designed based on the large extra-cellular loop of CD81 with known importance in the HCV E2 binding interaction. Our results showed that the stapled peptides exhibited significantly higher alpha-helicity and proteolytic stability as compared to their linear peptide counterpart. The optimal compound was found to have an EC50 value of ca. 17-39 mu M against different HCV subtypes and represented a new HCV membrane fusion inhibitor. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3547 / 3554
页数：8
相关论文
共 50 条
  • [31] Optimisation of peptide based inhibitors of full length Hepatitis C Virus NS3 protease
    Poliakov, A
    Johansson, A
    Åkerblom, E
    Lindeberg, G
    Hallberg, A
    Danielson, UH
    ANTIVIRAL RESEARCH, 2003, 57 (03) : A86 - A86
  • [32] Fusogenic Effect of Cholesterol Prevails over the Inhibitory Effect of a Peptide-Based Membrane Fusion Inhibitor
    Pattnaik, Gourab Prasad
    Chakraborty, Hirak
    LANGMUIR, 2021, 37 (11) : 3477 - 3489
  • [33] Peptide-eased inhibitors of the hepatitis C virus serine protease.
    Bailey, M
    Fazal, G
    Gorys, V
    Goulet, S
    Halmos, T
    Poirier, M
    Poupart, MA
    Rancourt, J
    Wernic, D
    s-Brunet, ML
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U1009 - U1009
  • [34] PEPTIDE ALDEHYDE INHIBITORS OF HEPATITIS-A VIRUS 3C PROTEINASE
    MALCOLM, BA
    LOWE, C
    SHECHOSKY, S
    MCKAY, RT
    YANG, CC
    SHAH, VJ
    SIMON, RJ
    VEDERAS, JC
    SANTI, DV
    BIOCHEMISTRY, 1995, 34 (25) : 8172 - 8179
  • [35] Synthesis of hepatitis B virus fusion inhibitors
    Schieck, Alexa
    Mueller, Thomas
    Boy, Garcia Regine
    Urban, Stephan
    Kunz, Horst
    Mier, Walter
    JOURNAL OF PEPTIDE SCIENCE, 2008, 14 (08) : 62 - 62
  • [36] NOVEL PEPTIDE-BASED MICROBIOCIDES INHIBITING HEPATITIS B VIRUS ENTRY BY PREVENTING VIRUS INTERACTION WITH THE CELL SURFACE
    Lucifora, J.
    Kowalski, I.
    Xia, Y.
    Brandenburg, K.
    Protzer, U.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S33 - S34
  • [37] Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors
    Granger, Brett A.
    Brown, Dean G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (21) : 5304 - 5307
  • [38] Inhibition of human caspases by peptide-based and macromolecular inhibitors
    Garcia-Calvo, M
    Peterson, EP
    Leiting, B
    Ruel, R
    Nicholson, DW
    Thornberry, NA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (49) : 32608 - 32613
  • [39] Peptide and peptide-based inhibitors of SARS-CoV-2 entry
    Schuetz, Desiree
    Ruiz-Blanco, Yasser B.
    Muench, Jan
    Kirchhoff, Frank
    Sanchez-Garcia, Elsa
    Mueller, Janis A.
    ADVANCED DRUG DELIVERY REVIEWS, 2020, 167 : 47 - 65
  • [40] Peptide-based amyloid-beta aggregation inhibitors
    Sehra, Naina
    Parmar, Rajesh
    Jain, Rahul
    RSC MEDICINAL CHEMISTRY, 2025, 16 (03): : 1083 - 1104
12345